Research in a small group of men with advanced prostate cancer found that a blood test that screens for a certain genetic mutation could help decide which of two types of drugs would be more likely to provide a longer lifespan.
The largest study to date of prostate cancer screening reinforces the existing evidence that the potential benefits of the test are outweighed by the harms of overtreatment for low-grade cancer that could be left untreated.
Combining multiple forms of radiation therapy with hormone treatments lengthens survival in men with aggressive prostate cancer.
Men whose PSA levels continue rising even after surgery or radiation therapy may have a new treatment option with the approval of the drug apalutamide.
Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.
Urinary incontinence is more common in women, but men experience it too, particularly as they get older. Whether it’s urge incontinence or stress incontinence, there are strategies and treatments that can help.
Surveys of over 900 men who were diagnosed with prostate cancer in the 1990s found that approximately 15% had some regret over their treatment choices. Study authors encourage doctors and patients to have frank and thorough discussions about about the risks and benefits of various forms of treatment for prostate cancer.
The debate about PSA screening for prostate cancer has been going on for decades, and research has been similarly divided. For most men, the best advice is to talk with your doctor so the benefits and risks of the test are clear.
In contrast to earlier research, a review of dozens of studies involving millions of men who had vasectomies found no proof that having a vasectomy increases a man’s risk of prostate cancer.
The results of two studies found that using the drug abiraterone in combination with other hormonal therapy drugs to treat aggressive prostate cancer produced more favorable results than the first-line therapy alone.